<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182218</url>
  </required_header>
  <id_info>
    <org_study_id>INC-ACO-2013-01</org_study_id>
    <nct_id>NCT03182218</nct_id>
  </id_info>
  <brief_title>Periprocedural Direct Oral Anticoagulant Management</brief_title>
  <acronym>RA-ACOD</acronym>
  <official_title>Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct oral anticoagulants (DOAC) are a new drug group that has been approved for chronic
      anticoagulation of patients in atrial fibrillation or suffering acute thrombosis, between
      others. The need of surgery of a patient in atrial fibrillation is round 10% per year.

      Due to DOAC short time of commercialization and the lack of experience, the proper management
      of DOAC when a patient in this treatment needs a scheduled or urgent procedure, has not yet
      been established. This fact may mean both the decrease of the anticoagulant treatment
      efficacy and the increase of the haemorrhage complications in the perioperative period.

      With the aim of gaining additional information about this aspect, a multicentre, prospective
      and observational study (classified by the spanish drug society, AEMPS, as non-interventional
      trial, EPA-SP) about the DOAC management, before a scheduled or urgent surgery, in normal
      clinical practice, is proposed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When an anticoagulated patient is scheduled for surgery or an invasive procedure, the
      physician's worry is how to achieve needing an optimal haemostasis without increasing the
      risk of thrombosis. For decades, the main drug for chronic anticoagulation has been
      antivitamin-k (warfarin or acenocoumarol). In the majority of patients, the periprocedural
      management proposal has been stopping the drug and giving a short acting anticoagulant for
      some days before surgery, known as bridging therapy strategy, mostly done with a
      low-molecular weight heparin (LMWH).

      The debate about the best perioperative management of the anticoagulated patients has
      increased with the arrival on the market of direct oral anticoagulants (DOAC), by the moment
      approved for long-term anticoagulation in patients with atrial fibrillation and for the
      treatment of pulmonary embolism. DOAC could be classified in two groups: direct inhibitors of
      thrombin (the only current available drug is dabigatran) and direct inhibitors of factor Xa
      (rivaroxaban, apixaban, edoxaban, and others soon to come). DOAC have pharmacokinetic
      characteristics that seem to favour stopping the drug for some days without substitution in
      the vast majority of the patients. Nevertheless, current lack of experience in the management
      of high doses of DOAC during the perioperative period, the absence of effective antagonists
      to reverse the anticoagulation, the unsuitable standardized laboratory monitoring and, also,
      the different pharmacokinetics between patients receiving these drugs, have made challenging
      to standardize the optimal management in the perioperative period. Some proposals have been
      published in last years from expert consensus, based on pharmacokinetic data, but DOAC short
      time of commercialization and the difficulties to interpret the post-hoc analysis from the
      randomized trials, for the heterogeneity of the included population and the wide kind of
      surgeries, most of them with low bleeding risk, have moved the spanish working group on
      perioperative management of haemostasis to plan a multi-institutional registry to gain
      experience and information in the periprocedural (urgent or scheduled) management of DOAC.

      The authors designed an observational, prospective, multicentre study including patients
      under long-term DOAC treatment for atrial fibrillation or treatment of venous thromboembolism
      who are scheduled or need an urgent procedure. Data collected were demographic, related with
      the DOAC management and with the possible haemorrhagic or thrombotic events with a follow-up
      of 30 day. A univariable analysis and a multivariate regression model were applied using all
      the available co-variables. Bilateral hypothesis contrast were considered significant if α &lt;
      0.05.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Periprocedural thrombotic complications</measure>
    <time_frame>1 month</time_frame>
    <description>Accumulative incidence rate of thrombotic events (cardiovascular, neurological, or venous thromboembolic event)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Periprocedural hemorrhagic complications</measure>
    <time_frame>1 month</time_frame>
    <description>Accumulative incidence rate of minor and major bleeding events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome of bridging therapy</measure>
    <time_frame>Between one week before and one month after procedural</time_frame>
    <description>Relationship between the incidence of complications and the use of bridging therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowing actual DOAC management in clinical practice</measure>
    <time_frame>Between one week before and one month after procedural</time_frame>
    <description>Composite of time of withdrawal of direct oral anticoagulant, use or not of low molecular weight heparin as bridge therapy, time of reintroduction of direct oral anticoagulant</description>
  </secondary_outcome>
  <enrollment type="Actual">1100</enrollment>
  <condition>Periprocedural Complication</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Direct oral anticoagulant</intervention_name>
    <description>Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin</description>
    <other_name>low molecular weight heparin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient under treatment with direct oral anticoagulant who requires a surgery or an
        invasive procedural, both scheduled or urgent.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age and older

          -  Under direct oral anticoagulant

          -  Urgent or scheduled surgery or invasive procedure needed

          -  Signed and dated informed consent form

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raquel Ferrandis Comes, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sabadell-Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Ribera</name>
      <address>
        <city>Alzira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc Salut Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Galdakao-Usánsolo</name>
      <address>
        <city>Galdakao</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Doctor Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Móstoles</name>
      <address>
        <city>Móstoles</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>40006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorcio H. General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluís Alcanyís</name>
      <address>
        <city>Xàtiva</city>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Pérez-Villacastín J, Pérez Castellano N, Moreno Planas J. Epidemiology of atrial fibrillation in Spain in the past 20 years. Rev Esp Cardiol (Engl Ed). 2013 Jul;66(7):561-5. doi: 10.1016/j.rec.2013.02.012. Epub 2013 May 28. Review.</citation>
    <PMID>24776206</PMID>
  </reference>
  <reference>
    <citation>Barrios V, Calderón A, Escobar C, de la Figuera M; Primary Care Group in the Clinical Cardiology Section of the Spanish Society of Cardiology. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol (Engl Ed). 2012 Jan;65(1):47-53. doi: 10.1016/j.recesp.2011.08.008. Epub 2011 Nov 4. English, Spanish. Erratum in: Rev Esp Cardiol (Engl). 2012 May;65(5):494.</citation>
    <PMID>22054913</PMID>
  </reference>
  <reference>
    <citation>Cea-Calvo L, Redón J, Martí-Canales JC, Lozano JV, Llisterri JL, Fernández-Pérez C, Aznar J, González-Esteban J. [Prevalence of low glomerular filtration rate in the elderly population of Spain. The PREV-ICTUS study]. Med Clin (Barc). 2007 Nov 17;129(18):681-7. Spanish.</citation>
    <PMID>18021608</PMID>
  </reference>
  <reference>
    <citation>Weitz JI, Eikelboom JW, Samama MM. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e120S-e151S. doi: 10.1378/chest.11-2294. Review.</citation>
    <PMID>22315258</PMID>
  </reference>
  <reference>
    <citation>Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy. 2011 Dec;31(12):1175-91. doi: 10.1592/phco.31.12.1175. Review.</citation>
    <PMID>22122180</PMID>
  </reference>
  <reference>
    <citation>Mavrakanas T, Bounameaux H. The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacol Ther. 2011 Apr;130(1):46-58. doi: 10.1016/j.pharmthera.2010.12.007. Epub 2010 Dec 24. Review.</citation>
    <PMID>21185864</PMID>
  </reference>
  <reference>
    <citation>Llau JV, Ferrandis R, Castillo J, de Andrés J, Gomar C, Gómez-Luque A, Hidalgo F, Torres LM. [Recommendations on use of direct oral anticoagulants in the perioperative period]. Med Clin (Barc). 2012 Oct;139 Suppl 2:46-50. doi: 10.1016/S0025-7753(12)70042-8. Review. Spanish.</citation>
    <PMID>23498073</PMID>
  </reference>
  <reference>
    <citation>van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Review.</citation>
    <PMID>20352166</PMID>
  </reference>
  <reference>
    <citation>Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost. 2012 Nov;108(5):876-86. doi: 10.1160/TH12-03-0209. Epub 2012 Sep 26. Review.</citation>
    <PMID>23014816</PMID>
  </reference>
  <reference>
    <citation>Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012 Mar 29;119(13):3016-23. doi: 10.1182/blood-2011-10-378950. Epub 2012 Feb 1. Review.</citation>
    <PMID>22302737</PMID>
  </reference>
  <reference>
    <citation>Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation. 2012 Sep 25;126(13):1573-6.</citation>
    <PMID>23008469</PMID>
  </reference>
  <reference>
    <citation>Llau JV, Ferrandis R. Letter by Llau and Ferrandis regarding article, &quot;Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation&quot;. Circulation. 2013 May 14;127(19):e616. doi: 10.1161/CIRCULATIONAHA.112.151506.</citation>
    <PMID>23671184</PMID>
  </reference>
  <reference>
    <citation>Ferrandis R, Castillo J, de Andrés J, Gomar C, Gómez-Luque A, Hidalgo F, Llau JV, Sierra P, Torres LM. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost. 2013 Sep;110(3):515-22. doi: 10.1160/TH12-11-0868. Epub 2013 Jul 11. Review.</citation>
    <PMID>23846475</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>February 16, 2018</last_update_submitted>
  <last_update_submitted_qc>February 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Raquel Ferrandis</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Periprocedural</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Dabigatran</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Edoxaban</keyword>
  <keyword>Direct oral anticoagulant</keyword>
  <keyword>Surgery</keyword>
  <keyword>Anaesthesia</keyword>
  <keyword>Novel oral anticoagulant</keyword>
  <keyword>Perioperative medicine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>CRD urgente 3.0</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://raacod.datarus.eu/es/docs</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>CRD programada 3.0</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>http://raacod.datarus.eu/es/docs</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>Protocolo ACOD 1.1</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://raacod.datarus.eu/es/docs</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>CI 1.1</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://raacod.datarus.eu/es/docs</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

